PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus (OTCQB: PVCT) announced that the USPTO has allowed patent application 16/688,319, which covers the use of PV-10 for treating hematologic cancers. This marks Provectus' first patent award in hematology. In vivo studies showed that mice with acute lymphoblastic leukemia treated with oral PV-10 had increased survival rates compared to control groups. Innovate Calgary is a co-assignee for this patent, with a co-inventor from the University of Calgary.

KNOXVILLE, TN, April 19, 2022 – Provectus (OTCQB: PVCT) announced proposals for its 2022 Annual Meeting on June 22, including a reverse stock split ranging from 1-for-10 to 1-for-50 and a corresponding authorized share reduction. Approval for these measures is contingent upon the reverse stock split passing. Other items on the agenda include director elections, executive compensation approval, and ratification of the independent accounting firm. A definitive proxy statement will follow the preliminary filing pending SEC review.

Provectus announced the addition of Dr. Aru Narendran to its Scientific Advisory Board. Dr. Narendran, a professor at the University of Calgary, is recognized for his significant contributions to pediatric oncology. His collaboration with Provectus over the past five years has led to preclinical research on the drug rose bengal sodium (RBS), which shows promise in treating various cancers including neuroblastoma and acute leukemias. The partnership has also resulted in multiple patents and unique discoveries related to RBS. Provectus values Dr. Narendran's insights to enhance its drug development efforts.

Provectus (OTCQB: PVCT) announced preclinical research on its investigational cancer immunotherapy, PV-10, presented at the AACR annual meeting in New Orleans. The research, led by Dr. Aru Narendran, demonstrates PV-10's cytotoxic effects on high-risk solid tumor cell lines, including breast and colorectal cancers. Key findings reveal PV-10’s ability to modulate apoptosis and autophagy pathways, and inhibit cancer cell migration. PV-10 has been administered in over 450 patients and is under investigation for both local and systemic treatment of various cancers.

Provectus (OTCQB: PVCT) announced the successful development of a second halogenated xanthene (HX) molecule, enhancing its existing pipeline that includes the clinical-stage rose bengal sodium (RBS). The newly synthesized HX, with a complex molecular name, expands Provectus' proprietary intellectual property portfolio. The company adheres to Quality-by-Design (QbD) principles and cGMP guidelines for its products. Vice Chair Dominic Rodrigues expressed optimism about the potential of this new small molecule in drug development, aiming for it to become a viable drug candidate.

Provectus (OTCQB: PVCT) presented data from an ongoing clinical trial of its investigational cancer immunotherapy PV-10 for treating metastatic neuroendocrine tumors (mNET) at the ENETS conference.

Involving 12 patients, the study showed a median progression-free survival (mPFS) of 9.4 months and a median overall survival (mOS) of 22.5 months. The safety profile was favorable, with mostly Grade 1 or 2 adverse events. Potential combination therapies could enhance patient outcomes. The findings support PV-10 as a monotherapy option for patients resistant to standard treatments.

Provectus (OTCQB: PVCT) announced the acceptance of two abstracts for presentation at the 20th Congress of the International Society of Ocular Oncology, scheduled for June 17-21, 2022, in Leiden, Netherlands. The first abstract is a phase 1 study on PV-10 for metastatic uveal melanoma (mUM) patients. The second highlights metabolic complete responses in mUM patients treated with PV-10. PV-10 is an investigational cancer immunotherapy administered intralesionally to induce immune responses against tumors, having been used in over 450 patients with various malignancies.

Provectus (OTCQB: PVCT) announced preclinical research on its cancer immunotherapy PV-10, which will be presented at the AACR annual meeting from April 8-13, 2022, in New Orleans. The accepted abstract focuses on PV-10's anticancer effects on adult solid tumors, revealing its impact on protein kinase signaling pathways involved in autophagy and cell migration. PV-10 has shown promise in inducing immune responses and is being studied for multiple uses in treating solid tumors. The research highlights the potential of PV-10 in combination therapies, particularly for checkpoint blockade-refractory diseases.

Provectus (OTCQB: PVCT) announced that data from its clinical trial of PV-10 for treating metastatic neuroendocrine tumors (mNET) will be presented at the European Neuroendocrine Tumor Society conference on March 10-11, 2022. The abstract, accepted for oral presentation, focuses on the Phase 1 study of intralesional PV-10, a novel cancer immunotherapy. PV-10 has shown promise in inducing T cell responses against tumors, with over 450 patients treated to date in various cancer types. The company is also exploring systemic administration for broader cancer treatment applications.